Key Dates

NOT-CA-21-063 - Notice of Intent to Publish a Funding Opportunity Announcement for Acquired Resistance to Therapy Network (ARTNet) (U54 Clinical Trial Not Allowed)

National Cancer Institute (NCI)

The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for a Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet) that will support the overall coordination and research aims of the ARTNet sites. This FOA will solicit U24 cooperative agreement applications from multidisciplinary groups that can assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative, and data management activities of the ARTNet.

It is anticipated that the research projects and resource cores of the individual ARTNet site will generate data, unique biospecimens, resources, models, and technologies that require a dedicated Coordinating and Data Management Center (CDMC) to centralize, integrate, and manage inter- and intra-network data, material, and know-how exchanges. The CDMC will function as a coordinating intermediary across the network as a whole and facilitate liaisons between ARTNet sites, NCI staff, and the cancer research community.

The principal functions of the CDMC are to: 1) facilitate the integration of the multicomponent ARTNet site activities; 2) support and enhance collective ARTNet findings; and 3) accelerate iteration of discoveries between basic, pre-clinical and clinical cancer research. It is envisioned that the CDMC will have national leadership and impact in addressing unmet needs to facilitate acquired resistance research.

ARTNet activities to be supported by the CDMC include, but are not limited to:

• Provide a centralized administrative infrastructure to coordinate ARTNet activities, which includes administrative, organizational, analytical, and collaborative support for basic, preclinical, and clinical cancer research studies;
• Facilitate and strengthen collaborations within the ARTNet, and promote ARTNet interaction and collaboration with other NCI-sponsored programs and resources;
• Provide multidisciplinary analytic expertise and application of statistical and computational tools to support ARTNet studies and collaborative research;
• Develop improved data integration and management methods to enhance ARTNet research capacity;
• Ensure ARTNet compliance with NIH and NCI regulatory, data and resource sharing, and publication policies;
• Assist the ARTNet to identify and develop collaborative opportunities which encourage and promote bi-directional bridging between basic, preclinical, and clinical science;
• Develop outreach activities to promote the exchange of scientific outcomes both within ARTNet and between ARTNet and the public; and
• Facilitate the implementation, management, and coordination of ARTNet steering committee and- specific working groups;

This Notice is being provided to allow potential applicants sufficient time to develop a responsive, multicomponent CDMC application. The FOA is expected to be published in Summer 2021 with an anticipated application due date in Fall 2021. Details of the planned pre-application webinar will be announced after publication of the FOA.
 

Applications are not being solicited at this time. 

Please direct all inquiries to:

For specific inquiries related to radiotherapy and radiation biology:

Michael Graham Espey, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7619
Email: [email protected]

For specific inquiries related to tumor biology and microenvironment:
Jeffrey Hildesheim, Ph.D.
National Cancer Institute
Telephone: 240-276-6230
Email: [email protected]

For specific inquiries related to preclinical evaluation for cancer therapy:
Percy Ivy, M.D.
National Cancer Institute
Telephone: 240-276-6107
Email: [email protected]